TY - JOUR
T1 - Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis
T2 - Associations with disease course and progression
AU - Lourenco, Pedro
AU - Shirani, Afsaneh
AU - Saeedi, Jameelah
AU - Oger, Joel
AU - Schreiber, William E.
AU - Tremlett, Helen
N1 - Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 2013/4
Y1 - 2013/4
N2 - Background: The use of oligoclonal bands (OCBs) and cerebrospinal fluid (CSF) parameters are established in the diagnosis of MS, but poorly as markers of disease. Objective: To investigate the role of OCBs in disease course and progression. Methods: CSF data for 1120 patients with MS were analyzed for associations between OCBs and CSF parameters and clinical data (disease course [relapsing-onset MS (ROMS) vs primary-progressive MS (PPMS)]), disability progression (proportion reaching Expanded Disability Status Scale 6 within 10 years of onset and progression index) and ethnicity. Results: Of patients with MS, 72.5% had detectable OCBs. For patients with detectable OCBs, 84.6% had ROMS and 15.4% PPMS versus 89.7% and 10.3%, respectively for those without detectable OCBs (p=0.04). Total CSF IgG and protein levels were higher in PPMS compared with ROMS (p<0.001). Disease progression appeared independent of OCB status. Patients with CSF (vs without) data were more likely to be male, older at onset, have PPMS and lack optic neuropathy at onset (p<0.001). Conclusions: OCB positivity and elevated total CSF IgG and protein were moderately associated with a PPMS disease course, but not disease progression. Patients with atypical clinical presentations were more likely to have had CSF work-up, suggesting a testing bias.
AB - Background: The use of oligoclonal bands (OCBs) and cerebrospinal fluid (CSF) parameters are established in the diagnosis of MS, but poorly as markers of disease. Objective: To investigate the role of OCBs in disease course and progression. Methods: CSF data for 1120 patients with MS were analyzed for associations between OCBs and CSF parameters and clinical data (disease course [relapsing-onset MS (ROMS) vs primary-progressive MS (PPMS)]), disability progression (proportion reaching Expanded Disability Status Scale 6 within 10 years of onset and progression index) and ethnicity. Results: Of patients with MS, 72.5% had detectable OCBs. For patients with detectable OCBs, 84.6% had ROMS and 15.4% PPMS versus 89.7% and 10.3%, respectively for those without detectable OCBs (p=0.04). Total CSF IgG and protein levels were higher in PPMS compared with ROMS (p<0.001). Disease progression appeared independent of OCB status. Patients with CSF (vs without) data were more likely to be male, older at onset, have PPMS and lack optic neuropathy at onset (p<0.001). Conclusions: OCB positivity and elevated total CSF IgG and protein were moderately associated with a PPMS disease course, but not disease progression. Patients with atypical clinical presentations were more likely to have had CSF work-up, suggesting a testing bias.
KW - CNS
KW - cerebrospinal fluid
KW - chronic progressive
KW - demyelinating autoimmune diseases
KW - ethnicity
KW - multiple sclerosis
KW - natural history studies (prognosis)
KW - oligoclonal IgG
KW - prognosis
KW - relapsing-remitting multiple sclerosis
UR - http://www.scopus.com/inward/record.url?scp=84876517388&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876517388&partnerID=8YFLogxK
U2 - 10.1177/1352458512459684
DO - 10.1177/1352458512459684
M3 - Article
C2 - 22961214
AN - SCOPUS:84876517388
SN - 1352-4585
VL - 19
SP - 577
EP - 584
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
IS - 5
ER -